TL;DR: Aetna, a CVS Health company, modified CPB 0517 covering breast ductal lavage and fiberoptic ductoscopy, effective January 5, 2026. Here's what billing teams need to act on now.
This update to the CPB 0517 Aetna system clarifies which indications clear the medical necessity bar and which land in experimental territory. The policy covers procedures billed under CPT codes 19030, 77053, 77054, 88112, and 88161. If your practice handles nipple discharge workups or intraductal lesion diagnosis, this coverage policy directly affects your claim outcomes.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Breast Ductal Lavage and Fiberoptic Ductoscopy |
| Policy Code | CPB 0517 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | Medium |
| Specialties Affected | Breast surgery, gynecology, radiology, pathology |
| Key Action | Audit active claims for ductal lavage and ductoscopy against updated indication criteria before submitting |
Aetna Breast Ductal Lavage and Fiberoptic Ductoscopy Coverage Criteria and Medical Necessity Requirements 2026
The Aetna breast ductal lavage and fiberoptic ductoscopy coverage policy draws a tight box around what qualifies as medically necessary. Get outside that box and you're looking at a claim denial.
For breast ductal lavage, Aetna covers one specific scenario: the procedure is used as an alternative to aspiration for diagnosing non-lactational sporadic nipple discharge, and only when direct nipple aspirate yields too little cellular material for adequate cytological analysis. That's a narrow window. The procedure has to be a fallback, not a first-line choice.
For fiberoptic ductoscopy, Aetna recognizes two covered indications. First, ductoscopy combined with cytology testing for diagnosing intraductal lesions in women with non-lactational sporadic nipple discharge — but only when accompanied by documented positive cytology. That documentation requirement is not optional. Second, ductoscopy used as a surgical guide for resection of known breast intraductal cancer, with ICD-10 codes C50.011 through C50.929 supporting the covered diagnosis range.
Aetna does not list prior authorization as an explicit requirement in CPB 0517, but given the narrow indications and the experimental designations described below, check your plan-level prior auth rules before scheduling these procedures. Prior auth requirements vary by product line and group contract. Don't assume fee-for-service rules apply to commercial plans.
For cytopathology billed alongside these procedures — CPT 88112 (liquid-based cytology with interpretation) and CPT 88161 (cytopathology smear preparation, screening, and interpretation) — documentation needs to clearly support the underlying indication. Reimbursement for the cytology codes hinges on the same medical necessity rationale as the primary procedure.
Aetna Breast Ductal Lavage and Fiberoptic Ductoscopy Exclusions and Non-Covered Indications
This is where most denials will come from. Aetna draws hard experimental lines across several indications that clinical teams may believe are reasonable.
Breast ductal lavage — including devices like the ForeCYTE Breast Health test, the Halo Breast Pap Test system, the MASCT System, and the Pro-Duct Catheter — is experimental for breast cancer screening, breast cancer risk assessment, and all other indications. Non-lactational mastitis (ICD-10 N61.0, N61.1) is explicitly called out as a non-covered treatment target. If your ordering providers are using ductal lavage as a screening tool or risk stratification approach, those claims will not hold up under this coverage policy.
Fiberoptic ductoscopy used for breast cancer screening is also experimental. No exceptions.
Three additional indications land in experimental territory under CPB 0517:
| # | Excluded Procedure |
|---|---|
| 1 | Breast ductal endoscopy combined with ductal lavage to evaluate the contralateral breast in women with ipsilateral breast cancer. The clinical value hasn't been established, and Aetna says so plainly. |
| 2 | Assessment of genetic methylation patterns in ductal lavage samples for breast cancer risk prediction. Insufficient peer-reviewed evidence. |
| 3 | miRNA analysis of breast ductal fluid for breast cancer detection. Same problem — no adequate evidence base. |
The real issue with these exclusions is that they cover approaches some oncology practices view as emerging tools. If your institution is running any of these as part of a high-risk breast program, get your compliance officer and billing consultant involved before January 5, 2026. Filing claims against excluded indications isn't a gray area — it's a denial waiting to happen.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Breast ductal lavage for non-lactational sporadic nipple discharge (when aspirate yield is insufficient) | Covered | 88112, 88161 | Must be alternative to aspiration, not first-line |
| Fiberoptic ductoscopy + cytology for intraductal lesion diagnosis with documented positive cytology | Covered | 88112, 88161 | Positive cytology documentation required |
| Fiberoptic ductoscopy as surgical guide for known intraductal breast cancer resection | Covered | C50.011–C50.929 | Diagnosis must support known intraductal cancer |
| Breast ductal lavage for breast cancer screening | Experimental | — | Includes ForeCYTE, Halo, MASCT, Pro-Duct devices |
| Breast ductal lavage for breast cancer risk assessment | Experimental | — | Insufficient peer-reviewed evidence |
| Breast ductal lavage for non-lactational mastitis treatment | Experimental | N61.0, N61.1 | Explicitly excluded |
| Fiberoptic ductoscopy for breast cancer screening | Experimental | — | Insufficient evidence |
| Ductal endoscopy + lavage for contralateral breast evaluation (ipsilateral breast cancer patients) | Experimental | — | Clinical value not established |
| Genetic methylation analysis of ductal lavage samples for cancer risk prediction | Experimental | — | Insufficient peer-reviewed evidence |
| miRNA analysis of breast ductal fluid for cancer detection | Experimental | — | Insufficient peer-reviewed evidence |
Aetna Breast Ductal Lavage and Fiberoptic Ductoscopy Billing Guidelines and Action Items 2026
Here's what your billing team needs to do before and after the January 5, 2026 effective date.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for ductal lavage claims now. Pull any active or pending claims that include CPT 88112 or 88161 paired with a ductal lavage or ductoscopy encounter. Confirm the indication matches one of the two covered scenarios. If it doesn't, hold the claim. |
| 2 | Flag screening and risk-assessment indications immediately. Any claim where the ordering indication is breast cancer screening, risk assessment, or contralateral breast evaluation is going to be denied under this policy. Work with your clinical team to determine whether the documented clinical picture supports a covered indication instead — before the claim goes out the door. |
| 3 | Verify positive cytology documentation for ductoscopy claims. For fiberoptic ductoscopy combined with cytology, the policy requires documented positive cytology. Make sure that documentation is in the chart and referenced in the claim record. A missing cytology report is an easy denial that's hard to appeal. |
| 4 | Check plan-level prior authorization rules for commercial products. CPB 0517 doesn't list explicit prior auth requirements, but Aetna commercial plan prior auth requirements vary. Run your payer-specific benefit check before scheduling ductoscopy procedures after the January 5, 2026 effective date. |
| 5 | Train clinical and coding staff on the experimental exclusions. The miRNA and methylation analysis exclusions are new enough that some providers may not know they're off the table. Brief your breast surgery and oncology coding teams on the full experimental list. A claim for genetic methylation analysis of ductal lavage fluid has zero path to payment under this policy. |
| 6 | Review your ICD-10 pairing strategy for ductoscopy claims billed for intraductal cancer resection. When billing fiberoptic ductoscopy as a surgical guide (the second covered indication), pair it with the appropriate C50 code from the C50.011–C50.929 range. The diagnosis code has to confirm known intraductal cancer — not suspected, not screening-related. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Breast Ductal Lavage and Fiberoptic Ductoscopy Under CPB 0517
CPT Codes Related to CPB 0517
| Code | Type | Description |
|---|---|---|
| 19030 | CPT | Injection procedure only for mammary ductogram or galactogram |
| 77053 | CPT | Mammary ductogram or galactogram, single duct, radiological supervision and interpretation |
| 77054 | CPT | Mammary ductogram or galactogram, multiple ducts, radiological supervision and interpretation |
| 88112 | CPT | Cytopathology, selective cellular enhancement technique with interpretation (e.g., liquid-based slide) |
| 88161 | CPT | Cytopathology smears, any other source; preparation, screening, and interpretation |
Note that 19030, 77053, and 77054 are listed as related codes in CPB 0517 — they support the diagnostic context for ductal procedures but coverage for each depends on the specific clinical indication and documentation. Breast ductal lavage billing that includes ductogram procedures should confirm the indication is documented as non-lactational sporadic nipple discharge.
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C50.011–C50.929 | Malignant neoplasm of breast — covered for known breast intraductal cancer when fiberoptic ductoscopy used as surgical guide |
| N61.0 | Inflammatory disorders of breast (non-lactational mastitis) — not covered for ductal lavage treatment |
| N61.1 | Inflammatory disorders of breast (non-lactational mastitis) — not covered for ductal lavage treatment |
| N63.0–N63.9 (and subcodes) | Unspecified lump in breast |
| N64.10–N64.29 (and subcodes) | Other disorders of breast (includes nipple discharge subcodes) |
| N64.3–N64.37 (and subcodes) | Other disorders of breast |
The N64 family is where non-lactational sporadic nipple discharge typically lands. Make sure you're using the most specific subcategory available in your EMR. Submitting a nonspecific breast disorder code when a nipple discharge-specific code exists is a quick path to a medical necessity audit.
Get the Full Picture for CPT 88112
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.